Applied DNA Sciences, Inc. reported a significant decline in financial performance for the third quarter of fiscal year 2025, ending June 30, 2025. The company generated total revenues of $304,393, a decrease of 36% from $472,789 in the same quarter of the previous year. Product revenues fell by 21% to $195,262, while service revenues dropped by 52% to $109,131. The gross profit for the quarter was $5,130, a stark decline from $242,601 in the prior year, resulting in a gross profit margin of just 2% compared to 51% a year earlier.
For the nine-month period ending June 30, 2025, Applied DNA reported total revenues of $1,937,506, up 19% from $1,625,863 in the same period of 2024. This increase was primarily driven by a 31% rise in product revenues, which reached $1,239,747, largely attributed to increased shipments in the Therapeutic DNA Production Services segment. However, the company still recorded a net loss of $9,988,942 for the nine months, compared to a loss of $3,774,563 in the previous year.
Strategically, Applied DNA has undergone significant restructuring, including the exit from its MDx Testing Services and DNA Tagging and Security Products and Services segments. This restructuring involved a workforce reduction of approximately 39%, aimed at focusing resources on its core Therapeutic DNA Production Services. The company anticipates a projected 31% reduction in payroll expenses as a result of these changes, although it will incur one-time charges of around $300,000 related to severance and other costs.
Operationally, the company has seen a notable shift in its business model, with a focus on nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. As of June 30, 2025, Applied DNA had cash and cash equivalents of $4,727,677, down from $5,852,363 at the end of the previous fiscal year. The company has expressed concerns about its ability to continue as a going concern, citing recurring net losses and negative operating cash flow.
Looking ahead, Applied DNA aims to capitalize on the growing demand for DNA and RNA production in biotherapeutics and diagnostics. The company is focused on enhancing its production capabilities and expanding its market share in these sectors. However, it remains cautious about the challenges posed by market conditions and the need for additional financing to support its operations and strategic initiatives.
About APPLIED DNA SCIENCES INC
Applied DNA Sciences, Inc. is a biotechnology company specializing in the production and detection of DNA and RNA. Its key offerings include Therapeutic DNA Production Services, molecular diagnostics, and DNA tagging for supply chain security. With a focus on expanding its mRNA therapeutic capabilities, the company targets pharmaceutical developers and healthcare providers. Recent initiatives include launching a new IVT platform and expanding pharmacogenomics testing services, addressing significant market opportunities in biotechnology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.